In addition to nivolumab, pembrolizumab (another anti-PD-1 antibody) and the combination of dabrafenib plus trametinib (for patients with BRAF V600-activating mutation) have also been approved by the FDA and recommended as adjuvant treatment for resected stage III melanoma, although their clinical trials have different populations. Here, BRAF is linked to melanoma.